Current Trends in Gynecologic Oncology

Review Article Open Access

Anemia Associated with Gynecological Cancer and Risk Factors for Lower Extremity Lymphedema Following Surgery for Cervical and Endometrial Cancer

Dimcho Bachvarov*

Department of Obstetrics and Gynaecology, Columbia University College of Physicians and Surgeons, United States

Abstract

Radiotherapy (RT) serves as an important adjuvant treatment. Pathological findings classify cervical cancer patients who undergo an upfront radical hysterectomy into low-, intermediate-, and high-risk groups. For low-risk groups, evidence-based guidelines recommend no adjuvant treatment, for intermediate-risk groups, adjuvant RT and chemotherapy, and for high-risk groups, adjuvant RT and chemotherapy. Resected endometrial cancer is treated with RT, chemotherapy, or both, depending on the tumor's stage and histologic grade.

Introduction

After surgery for cervical and endometrial cancer, lymphedema is a common complication that can significantly affect patients' quality of life. Swelling in the arms, legs, or other parts of the body is called lymphedema when the lymphatic system is damaged. Following surgery for cervical and endometrial cancer, there are a number of risk factors for lymphedema. A well-known side effect of gynecological cancer surgery is lymphedema of the lower extremities (LELs), with an incidence of up to 78.7 percent. Because LEL not only impairs motor function but also has the potential to progress to cellulitis, which ultimately lowers the quality of life for some patients, it is essential that physicians address LEL as soon as possible [1]. In this way, it is essential to distinguish the important gamble elements to forestall LEL. The number of lymph nodes (LNs) removed during surgery is significantly increased when pelvic LN dissection is performed. Compared to intracavitary RT (ICR), external beam RT (EBRT) that targets the entire pelvis is also a significant factor in the development of LEL in patients with cervical and endometrial cancer (CEC). However, there is a lack of precise information regarding the risk factors and prevalence of LEL in patients undergoing primary surgery for CEC with or without RT. Recent treatment modalities like sentinel LN biopsy (SLNB) and intensity-modulated RT (IMRT) have not been the subject of many studies that have looked into the relationship between the onset of LEL and these treatments.

The scope of the surgery: A major risk factor for lymphedema is the extent of the surgery, which may include the removal of lymph nodes.

Therapeutic radiation: There is a risk of lymphedema and damage to the lymphatic system from radiation therapy administered to the pelvic area.

Obesity: Following surgery for endometrial and cervical cancer, obesity is a risk factor for lymphedema. This is on the grounds that overabundance body weight can overburden the lymphatic framework [2-4].

Age: Due to aging-related changes in the lymphatic system, older patients may be more likely to develop lymphedema.

Infection: Following surgery, an infection that causes additional damage to the lymphatic system can increase the risk of lymphedema.

Insufficiency of the veins over time: After surgery, people who have chronic venous insufficiency, in which the veins in their legs have been damaged and are unable to effectively pump blood back to the heart, may experience lymphedema more frequently.

Previous experiences with lymphedema: Patients who have recently had lymphedema or who have a family background of lymphedema might be at a higher gamble of creating lymphedema following a medical procedure [5].

A thorough history and physical examination are typically used to make the diagnosis of lymphedema. Starting phases of lymphedema start with a delicate pitting edema, ordinarily in a one-sided limit. After some time, ongoing edema animates provocative changes in the subcutaneous space [6]. As a result of these changes, the skin thickens and indurates, eventually leading to a non-pitting edema with fibrotic changes to the skin and subcutaneous tissues. In most cases, the lymphedematous extremity is examined in a clinic setting. In order to evaluate changes in the condition of the involved extremity, evaluation involves taking series of measurements over time. Measurements of the contralateral extremity are used as a control if it is not involved. If the anatomical points of measurement are not standardized, there may be a significant amount of variability among observers. At our establishment, the furthest point is estimated as follows: middle finger, near the metacarpophalangeal (MCP) joint and the proximal interphalangeal (PIP) joint; wrist proximal to the styloid; four inches from the olecranon in the forearm; elbow stretched out at wrinkle; four inches in front of the olecranon, mid-upper arm; eight inches from the olecranon to the axilla. These measurements are taken of the lower extremity: near the metatarsophalangeal (MTP) in the instep; ankle in the vicinity of the malleoli; six inches from the infra-patellar

***Corresponding author:** Dimcho Bachvarov, Department of Obstetrics and Gynaecology, Columbia University College of Physicians and Surgeons, United States, E-mail: Bachvarov @gmail.com

Received: 01-Apr-2023, Manuscript No. ctgo-23-98554; **Editor assigned:** 03-Apr-2023, PreQC No. ctgo-23-98554 (PQ); **Reviewed:** 17-Apr -2023, QC No. ctgo-23-98554; **Revised:** 21-Apr-2023, Manuscript No. ctgo-23-98554 (R); **Published:** 28-Apr -2023, DOI: 10.4172/ctgo.1000148

Citation: Bachvarov D (2023) Anemia Associated with Gynecological Cancer and Risk Factors for Lower Extremity Lymphedema Following Surgery for Cervical and Endometrial Cancer. Current Trends Gynecol Oncol, 8: 148.

border of the calf; knee at the popliteal crease; mid-thigh six inches proximal to the unrivaled patellar boundary; eight to ten inches in front of the superior patellar border in the groin. In the clinical assessment, associated pain and fatigue are also frequently recorded. Last but not least, the Lymphedema Breast Cancer Questionnaire (LBCQ), a validated instrument for assessing lymphedema symptoms , is given to all patients to fill out.

While imaging is utilized, the most well-known methodology for determination is backhanded radionuclide lymphoscintigraphy . An appropriate radiolabeled tracer, such as 99mTc-antimony sulfide colloid or 99mTc-labeled human serum albumin, must be injected either intradermally or subcutaneously as part of this procedure.

The following are diagnostic criteria for lymphatic dysfunction

1) Deferred, awry or missing perception of provincial lymph hubs

2) Asymmetrical lymphatic channel visualization

3) Lymphatic collateral channels

4) Vascular structures that are broken up; furthermore

5) Representation of the lymph hubs of the profound lymphatic framework. "dermal back-flow" is thought to be abnormal.

As a result of lymphatic and/or venous hypertension, it is interpreted as representing the extravasation of lymph fluid into the interstitium. Past lymphoscintigraphy, attractive reverberation imaging and electronic pivotal tomography have clinical utility. The structural changes brought on by lymphedema can be objectively documented using these imaging methods. Ongoing advances in the attractive reverberation approach have worked on the perception of lymphatic vascular irregularities in both nonenhanced and contrast-enhanced applications. We have followed a procedure similar to that outlined by Arrive et al. at our institution. Contrast injection is not required in this procedure, which is comparable to MR lymphography of the retroperitoneal region. A fast spin-echo, three-dimensional spin-echo sequence is used in MR lymphography. A three-dimensional isotropic MR lymphography protocol's primary benefit is the ability to acquire source images from thinner sections [7]. Maximum intensity projection (MIP) and multiplanar reformatted (MPR) images can be produced by processing image data optimally with thinner images. MR lymphography likewise permits the possible benefit of a three-layered evaluation of the furthest point, hence possibly considering the estimation of limit volumes.

In the treatment of patients with lymphedema of the upper and lower extremities, indocyanine green lymphography has emerged as an important imaging method. Pathophysiological lymphedema severity can be categorized using indocyanine green lymphography in real time without the need for radiation. For lymphatic surgery, it has also been reported that this method is useful for intraoperative navigation. The normal "linear" pattern of lymphography shifts to an abnormal "dermal backflow" pattern as secondary arm, leg, and facial lymphedema progresses. With this imaging, dermal reverse examples can be envisioned as a gentle dermal discharge 'sprinkle' design, moderate dermal reverse 'stardust' design, or extreme dermal reverse 'diffuse' design. The progression of the lymphography pattern may be related to the lymphatic system's pathology

Bioelectric impedance spectroscopy analysis is a new method for diagnosing lymphatic edema in the clinic. The method compares body fluid compartments by using resistance to electrical current. It has been deemed a method for evaluating patients with suspected lymphedema that is both cost-effective and reproducible. The procedure considers painless evaluation of extracellular liquid in the limits. Because it is accurate and repeatable, the method is likely to be used more and more in the early detection and treatment of lymphedema. Gynecological cancer-related anemia, including ovarian, cervical, and endometrial cancers, is frequently associated with anemia, a common condition. Anemia is when there are not enough red blood cells or hemoglobin in the body to carry oxygen to the tissues. This can prompt weariness, shortcoming, and windedness, among different side effects.

In gynecological malignant growths, sickliness is much of the time brought about by a blend of elements, including blood misfortune because of medical procedure or different therapies, and the actual disease. Anemia can result from cancer cells interfering with the bone marrow's production of red blood cells [8-11]. Anemia can also be brought on by bone marrow damage caused by some cancer treatments, such as chemotherapy and radiation therapy. Gynecological cancer patients' quality of life can be significantly impacted by anemia symptoms. Shortness of breath can limit physical activity, and fatigue and weakness can make it difficult to perform daily tasks. Because the body needs enough oxygen to respond to therapy, anemia can also affect how well cancer treatments work. The therapy of pallor in gynecological disease patients ordinarily includes a blend of methodologies, including blood bondings, prescription to invigorate red platelet creation, and dietary changes. Common treatments for cancer patients with anemia include iron supplements and erythropoietin-stimulating agents (ESAs). ESAs are meds that invigorate the development of red platelets by the bone marrow and can assist with further developing sickliness and diminish the requirement for blood bondings.

Conclusion

Several risk factors have been identified for lymphedema, a common complication following surgery for cervical and endometrial cancer. These incorporate the degree of medical procedure, radiation treatment, weight, age, contamination, ongoing venous deficiency, and past history of lymphedema. Patients must be aware of these risk factors and take precautions to reduce their likelihood of developing lymphedema, such as exercising, avoiding clothing that is too tight, and seeking prompt treatment for infections. All in all, weakness is a typical condition that is frequently connected with gynecological diseases, including ovarian, cervical, and endometrial malignant growths. Anemia can be brought on by a number of things, including the cancer itself and blood loss from surgery or other treatments. The therapy of paleness in gynecological disease patients commonly includes a mix of techniques, including blood bondings, prescription to animate red platelet creation, and dietary changes. In order to improve the prognosis and quality of life of gynecological cancer patients, early detection and treatment of anemia are essential.

References

1. May KE, Conduit-Hulbert SA, Villar J, Kirtley S, Kennedy SH, et al. (2010) Peripheral biomarkers of endometriosis: a systematic review. Hum Reprod Update 16:651–674.
2. Lee KK, Jharap B, Maser EA, Colombel JF (2016) Impact of concomitant endometriosis on phenotype and natural history of inflammatory bowel disease. Inflamm Bowel Dis 22:159-163.
3. Liu E, Nisenblat V, Farquhar C, Fraser I, Bossuyt PM, et al. (2015) Urinary biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev 23:12.
4. Matorras R, Ocerin I, Unamuno M, Nieto A, Peiro E ,et al (2007) Prevalence of endometriosis in women with systemic lupus erythematosus and Sjögren's syndrome. Lupus 16:736-740.
5. Healey M, Cheng C, Kaur H (2014) To excise or ablate endometriosis? A

prospective randomized double-blinded trial after 5-year follow-up. J Minim Invasive Gynecol 21:999-1004.

6. Azzopardi JG, Evans DJ (1971) Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium. J Pathol 104: 247-251.
7. Albores-Saavedra J, Rodríguez-Martínez HA, Larraza-Hernández O (1979) Carcinoid tumors of the cervix. Pathol Annu 14 :273-291.
8. Kubo T, Watanabe H Neoplastic argentaffin cells in gastric and intestinal carcinomas. Cancer 27:447-454.
9. Jadoul P, Donnez J (2003) Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 80:1315-1324.
10. Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP (1998) Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 91:349-354.
11. Gluckman JL, McDonough J, Donegan JO, Crissman JD, Fullen W, et al. (1981) The free jejunal graft in head and neck reconstruction. Laryngoscope 91:1887-1895.